Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effectsRamat Gan, Israel, March 03, ...

Why retinoic acid is effective in this setting but not against primary tumors, has been speculated about for nearly 50 years. Scientists resolved the mystery, showing the drug 'hijacks' a normal ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Vir Biotechnology, Inc. ( NASDAQ: VIR) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated ...